HalioDx is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.
As an immunologist, I founded HalioDx in 2014 with my former partners at Ipsogen and Jérôme Galon, a world specialist in cancer immunology. HalioDx implements a radically new approach to cancer diagnosis based on the analysis of the immune response: by precisely measuring the anti-tumour immune response of patients, we enable doctors to determine the severity of the disease, regardless of the cancer stage or molecular profile. Using this measurement, they should also be able to predict the response to treatment of their patients, including immunotherapies, which are at the core of the MI project.
To drive these innovations, HalioDx relies on a team of 80 employees that has already established its expertise in cancer diagnosis and has enabled the buyout of the company Ipsogen by the Qiagen group in 2011, after a successful industrial career and stock market performance. Again independent, HalioDx is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.#industry
Together, we pursue a simple goal: to better understand the alterations of energetic metabolism in pancreatic cancer cells
AMU, IPC, CRCM
MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.
Marseille Immunopôle (Marseille Immunology Center) has the potential to provide precious help to open new diagnostic and therapeutic pathways and to provide our patients with even more options.
Our aim is simple: to position ourselves upstream of the diagnosis and to propose innovative treatments to patients
AMU, IPC, CRCM